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The epidemiology of juvenile idiopathic arthritis (JIA) is variable worldwide. In particular, a wide disparity exists in
the prevalence of the diverse disease subtypes across different geographic areas. The therapeutic approach to JIA is
not standardized and no established and widely accepted guidelines are available. In the past decade, there have
been important progresses in the management of the disease, but the availability of the novel and costly biologic
medications is not uniform throughout the world. This issue may have significant impact on disease prognosis, with
children living in poorer countries being at greater risk of accumulating disease- and treatment-related damage
than children followed in Western pediatric rheumatology centers. The multinational study of the EPidemiology,
treatment and Outcome of Childhood Arthritis (EPOCA study) is aimed to obtain information on the frequency of
JIA subtypes in different geographic areas, the therapeutic approaches adopted by pediatric rheumatologists
practicing in diverse countries or continents, and the disease and health status of children with JIA currently
followed worldwide. Parent- and child-reported outcomes are meant to be recorded through the administration of
a new multidimensional questionnaire, the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). The first
step of the study is based on the translation and cross-cultural adaptation of the questionnaire in the national
language of each participating country. Each center is, then, asked to enroll a sample of consecutive JIA patients,
who should undergo a retrospective assessment and a cross-sectional evaluation, including completion of the
JAMAR, a standardized joint examination, and the assessment of articular and extra-articular damage. At the end of
May 2012, 124 centers in 55 countries have agreed to participate in the study. The JAMAR has been or is currently
being translated in 38 national languages. The target patient sample is more than 10,000 JIA children worldwide.
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Background
Juvenile idiopathic arthritis (JIA) is a chronic inflamma-
tory disease of presumed autoimmune etiology that affects
~1 of 1,000 children worldwide [1]. It is the most common
chronic rheumatic disease in the pediatric age and an
important cause of short-term and long-term disability. It* Correspondence: alessandroconsolaro@ospedale-gaslini.ge.it
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reproduction in any medium, provided the oris a heterogeneous condition, which is classified in 7 dif-
ferent categories based on the clinical manifestations
observed in the first 6 months after onset [2,3]. Some of
these categories may represent different diseases, charac-
terized by distinct modalities of presentation, clinical fea-
tures, immune-pathogenesis and, in some cases, genetic
background. The current International League of Associa-
tions of Rheumatology (ILAR) classification of JIA [2,3]
has the merit of having solved the drawback of the previ-
ous heterogeneity in nomenclature and criteria between
Europe and North America. However, it has been subjectral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the clinical parameters used to separate patients in the
various categories, namely the number of affected joints
and the presence of psoriasis, may not lead to identify
homogeneous disease subgroups [4].
The epidemiology of JIA is known to be variable world-
wide. In particular, a wide disparity exists in the prevalence
of the diverse disease subtypes between different coun-
tries. Although in the Western world the most common
category is represented by oligoarthritis, this subtype is
rare in countries such as Costa Rica, India, New Zealand,
and South Africa, where polyarthritis predominates [5-8].
Similar discrepancies have been reported for juvenile
spondyloarthropaties and for iridocyclitis, which is the
main extra-articular complication of some JIA subsets,
particularly those characterized by the presence of anti-
nuclear antibodies (ANA). However, little data exists on
the epidemiology of JIA. Furthermore, most studies have
involved single countries and the comparison of the distri-
bution of JIA categories across different geographic areas
has seldom been attempted.
A number of therapeutic options are available for the
management of JIA, ranging from NSAIDs to systemic
or intra-articular corticosteroids, to the traditional dis-
ease modifying antirheumatic drugs (DMARDs), to the
novel biologic agents [1,9-11]. However, although treat-
ment recommendations and standards of care for JIA
have recently been published [12,13], the therapeutic ap-
proach to JIA is not standardized and no treatment
guidelines have been prospectively evaluated, inter-
nationally accepted, and widely and systematically imple-
mented. As a result, the therapeutic choices for the
management of individual patients are likely variable
between pediatric rheumatologists practicing in single or
different countries.
In the past decade, there have been several important
advances in the management of JIA. In particular, the
introduction of biologic agents holds great promise for the
treatment of patients who are at greatest risk of develop-
ing irreversible structural damage to joints and permanent
physical disability. A recent CARRAnet study found that
45% of JIA patients in the US are exposed to biologic
DMARDs [14]. However, the availability of biologic drugs
is not uniform around the world. Due to their high cost,
these medications or some of them may not be afforded
by the national health care system of poorer countries or
by the families of children living in these countries. As a
result, many children with JIA around the world may not
entirely benefit from the recent progresses in disease treat-
ment. For some of these children, particularly those with
the more severe systemic or polyarticular subtypes, the ad-
ministration of high and prolonged doses of corticoster-
oids may be the sole therapeutic option to control disease
activity symptoms. As a consequence, they are exposed toa high risk of experiencing serious and potentially devas-
tating corticosteroid-related side effects. Altogether, these
issues may have significant impact on disease prognosis
and may place children living in poorer countries at
greater risk of accumulating disease-related or treatment-
related damage than children followed in Western
pediatric rheumatology centers.
Owing to the aforementioned differences in epidemi-
ology, treatment approaches, and availability of medica-
tions, there is likely an important variability in the
outcome of children with JIA around the world. Although
a number of long-term outcome surveys have been carried
out in the last 4 decades [15-17], most of these studies
have involved single centers or a few countries in the same
geographic area (e.g., Scandinavia). The comparison of JIA
disease outcomes between different parts of the world has
never been attempted. Furthermore, most studies have
evaluated patients with many years of disease duration,
whereas the outcomes achieved with the present treat-
ment, that is, the disease status of children currently fol-
lowed in pediatric rheumatology centers, has seldom been
investigated [18].
An important shortcoming of existing outcome studies
lies in the use of a wide variety of clinical measures,
which hampers comparability of results [16]. Further-
more, most analyses have focused only on specific
aspects of disease outcome, such as remission, functional
disability, radiographic damage, or health-related quality
of life (HRQL). In addition, children’s self-reported
assessments have been seldom incorporated.
Most clinical measures currently used to assess the
disease status, particularly functional ability and HRQL
questionnaires, are lengthy and complex [19]. For this
reason, they are rarely applied in standard clinical prac-
tice to assess patient status and to monitor therapeutic
response and disease course over time. However, it has
been recommended that regular use of quantitative mea-
sures in daily practice may lead to improve the quality of
patient care. To give an example, it has been suggested
that the implementation of a treat-to-target strategy,
based on treatment escalation if goal Juvenile Arthritis
Disease Activity Score (JADAS) [20,21] is not reached,
in clinical practice may improve disease outcome [22].
Furthermore, it is widely agreed that integration of
parent- and child-reported outcomes in daily care may
facilitate concordance with physician’s choices and com-
pliance with therapeutic prescriptions [23-25]. To reach
this goal, there is a need for outcome measures that are
simple and easy to apply. In addition, to facilitate com-
parability of outcome data across different centers, such
instruments need to be widely agreed upon and should
be translated, cross-culturally adapted and validated in
different languages according to established international
guidelines [26].
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includes all main parent- and child-reported outcomes
used in the clinical evaluation of children with JIA has
been developed [27]. This tool, named Juvenile Arthritis
Multidimensional Assessment Report (JAMAR), may be
well suited to collect parent- and child-reported infor-
mation in standard clinical care.
Aims of the study
To address the aforementioned issues, a multinational
study of the EPidemiology, treatment and Outcome of
Childhood Arthritis (EPOCA study) has been launched.
This project is primarily aimed to obtain information on
the frequency of JIA subtypes in different geographic
areas, the therapeutic approaches followed by pediatric
rheumatologists from diverse countries or continents, and
the current disease and health status of children with JIA
followed worldwide. Additional objectives are to investi-
gate the availability of biologic medications in different
countries, to foster the regular use of standardized quanti-
tative clinical measures in the clinical assessment of chil-
dren with JIA in standard clinical care, and to promote the
embracement of a uniform set of outcome measures
across international pediatric rheumatology centers.
Methods
Study design and patient selection
To obtain figures generalizable on a worldwide basis, the
involvement of a large number of countries is aimed for.
To reach this goal, participation in the study has been
first proposed to the national coordinating center of all
countries belonging to the Pediatric Rheumatology
International Trials Organization (PRINTO), and to one
pediatric rheumatology center in the US and Canada.
Once the contacted center had agreed to participate in
the study, the center was asked to offer the participation
in the study to any other pediatric rheumatology center
in the country that were meant to be potentially inter-
ested in joining the project.
To ensure that the data regarding the epidemiology,
treatment and outcome of JIA are reliable, the collection
of a representative sample of the patients followed at each
participating center is planned. Each centre is, then, asked
to enroll 100 consecutive and unselected patients meeting
the ILAR criteria for JIA or, if the centre does not expect
to see at least 100 patients within 6 months, to enroll all
consecutive and unselected patients meeting the same
criteria seen within the first 6 months after the study start.
Translation and cross-cultural adaptation of the JAMAR
Because the parent- and child-reported outcomes are
meant to be recorded through the administration of the
JAMAR, the first step of the study was based on the trans-
lation and cross-cultural adaptation of the questionnaire inthe national language of each participating country. The
translation of the questionnaire is conducted following a
standard procedure [26]. In brief, cross-culturally adapted
translation in the national language of the country of the
standard-English version of the parent and child versions of
the JAMAR is first made by at least 2 (preferably 3) inde-
pendent translators. The forward translators and 1 or 2
other individuals not involved in translation procedures
then meet to reach consensus, in order to obtain prelimin-
ary unified versions from the forward translations. Next,
the preliminary version of the questionnaires is back-
translated by at least 2 (preferably 3) independent native-
English translators. Backward translations are reviewed by
the PRINTO Coordinating Center staff, with specific ex-
pertise in translations issues, to verify their correspondence
with the original standard-English versions of the question-
naire. The PRINTO investigators then send their com-
ments to the national coordinator. Local forward and
backward translators finally meet to discuss and reconcile
the comments received from the PRINTO staff. The pur-
pose of the meeting is to reach consensus among transla-
tors on the second unified translation of the questionnaires.
In the subsequent step, the second versions of the
JAMAR is administered, using a probe technique, to 10
parents of children with JIA and to 10 children of differ-
ent educational background, to confirm parents’ and
children’s understanding of questionnaire items among
the target population. A health professional, familiar
with the meaning of each item, submits the question-
naire to parents and children and asks them to review
each question. The questions that are not correctly
interpreted by 20% or more of the parents or children
are reviewed by the national coordinating center and
revised accordingly. In case modifications to the second
unified forward version are needed, all forward and
backward translators convene in a final meeting to dis-
cuss the results of the probe technique. The purpose of
this meeting is to reach consensus among translators on
the final unified national language-version of the
questionnaires.
Study assessments
Each JIA patient enrolled in the study should receive a
retrospective evaluation, based on the review of the clin-
ical chart, and a cross-sectional assessment, made by the
attending physician at the time of the study visit. Prior
to the study visit, a parent of the child and the child
him/herself, if aged at least 7-8 years, should complete
the national-language translation of the parent proxy-
report and child self-report version of the JAMAR, re-
spectively. The parents or guardians of all children or
the children themselves (as appropriate) should provide
written informed consent to participation in the study.
Each participating center should have obtained the
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committee if required by the national laws.
Retrospective assessments include: demographic data;
ILAR category and detail of ILAR criteria met by the pa-
tient, including descriptors/exclusions and history of irido-
cyclitis; positive family history for autoimmune diseases;
results of ANA, rheumatoid factor, and HLA-B27 deter-
minations; history of macrophage activation syndrome
(MAS) or other co-morbid conditions; registration of drug
therapies received by the patient from disease onset to
cross-sectional assessment. Information regarding the
availability of specific biologic medications in each country
will be sought for through separate survey.
Cross-sectional assessment includes a standardized joint
examination, the physician’s global rating of the level of dis-
ease activity, the assessment of the presence of ongoing
enthesitis, dactylitis, active uveitis, and MAS, the physician’s
rating of disease status (remission, flare, continued disease
activity) and course (much or slightly improved, stable,
slightly or much worsened) on categorical scales, the regis-
tration of the therapeutic decisions made by the attending
physician at the end of the visit, and the assessment of the
amount of articular and extra-articular damage through the
Juvenile Arthritis Damage Index (JADI) [28]. Acute phase
reactants are tested if clinically indicated.
The JAMAR [27] includes the following 15 measures/
items: 1) assessment of physical function through the
JAFS [19]; 2) rating of the intensity of child’s pain on a
21-numbered circle VAS [29]; 3) assessment of HRQL,
through the PRQL [30]; 4) rating of child’s overall well-
being on a 21-numbered circle VAS [29]; 5) assessment
of the presence of pain or swelling in the following joints
or joint groups: cervical spine, lumbo-sacral spine,
shoulders, elbows, wrists, small hand joints, hips, knees,
ankles, and small foot joints; 6) assessment of morning
stiffness; 7) assessment of extra-articular symptoms
(fever and rash); 8) rating of the level of disease activity
on a 21-numbered circle VAS [29]; 9) rating of disease
status at the time of the visit as remission, continued ac-
tivity or relapse; 10) rating of disease course from previ-
ous visit as much improved; slightly improved; stable;
slightly worsened; or much worsened; 11) check-list of
the medications the child is taking; 12) check-list of side
effects of medications; 13) report of difficulties with
medication administration; 14) report of school pro-
blems caused by the disease; 15) a question about satis-
faction with the outcome of the illness [31]. The JAMAR
is available in 2 versions, one for parent proxy-report
and one for child self-report, with the suggested age
range of 7-18 years for use as self-report.
To compare the parent- and child-reported informa-
tion obtained for children with JIA with that of a healthy
children population, each national coordinating center is
asked to administer the JAMAR to around 100 parentsof healthy children and around 100 healthy children
aged more than 7-8 years. This sample can be repre-
sented by the healthy brothers and sisters, other relatives
(e.g. cousins), or friends of JIA patients included in the
study. In case of healthy brothers and sisters of JIA
patients, the parent is asked to complete the JAMAR for
both the patient and the healthy sibling(s) at the time of
the visit. The healthy sibling(s) can complete the
JAMAR at the time of the visit (if present) via tablet,
personal computer in the waiting room or at home via
internet (a user specific password is automatically gene-
rated by the PRINTO web database). Data are collected
on an sql web database placed on an https platform on
the dedicated PRINTO server. Centres are allowed to
collect data via web through the PRINTO member area
or alternatively on paper.Preliminary results
At the end of October 2012, 124 centers in 54 countries
have shown their interest to participate in the study
(Table 1 and Figure 1). The JAMAR has been or is cur-
rently being translated and cross-cultural adapted in 38
national languages. The number of completed translations
is 33. Data collection has already been started in 18 coun-
tries, and has been completed in 4 countries with more
than 1,800 JIA patients and nearly 400 healthy controls
already collected. The study is planned to be completed by
June 2013 and the results of data analyses will likely be
available by the end of 2013. The target patient sample is
more than 10,000 children worldwide.
Figure 1 Geographic distribution of the countries involved in the EPOCA study.
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So far, only a few pediatric rheumatology centers in the
United States and Canada have been included in the
study. Therefore, the information collected for this geo-
graphic area will be very limited and will not enable the
comparison of the therapeutic approaches across differ-
ent institutions within each country. This limitation will
also hamper the appreciation of whether the governmen-
tal cost restrictions in Canada might affect the prescrip-
tion policy regarding biologic medications in Canadian
versus US centers. To reduce this shortcoming of the
study, we plan to include more North American centers
in the next future. We recognize that because most cen-
ters involved in the study belong to PRINTO, the study
is dependent on the referrals to the PRINTO-related
pediatric rheumatologists. Furthermore, the results of
the epidemiologic analysis will reflect the epidemiology
of patients referred to pediatric rheumatologists and will
not account for patients referred to adult rheumatolo-
gists and general pediatricians. We should finally ac-
knowledge that although the study is intended to be a
global project, it is neither aimed to optimize recruit-
ment in areas where there is not pediatric rheumatolo-
gists nor to establish recommendations or standards of
care for JIA.
Conclusions
The EPOCA study is a huge and ambitious effort aimed
to get an overview on a worldwide basis of the geographic
distribution of the various JIA phenotypes, the treat-
ment approaches adopted by international pediatricrheumatologists, and the current outlook of children with
JIA followed in pediatric rheumatology centers in different
countries. The achievement of large-scale figures on the
frequency of JIA categories throughout the word may pro-
vide the rationale for devising changes in the present dis-
ease classification and for refining the strategy of future
genetic and pathogenetic investigations. The comparison
of the management policies of pediatric rheumatologists
practicing in diverse geographic and clinical settings may
stimulate the need for a better standardization of the
therapeutic approaches and the development of data-
driven management guidelines. In working out the data,
particular attention will be paid to the evaluation of the
relationship between the availability of biologic medica-
tions in a particular country and the outcome of children
followed in the country. The information obtained with
the EPOCA study will help make national and inter-
national organizations and health care providers aware of
the existence of inequalities in the access to biologic medi-
cations in different area of the world and of the impor-
tance of the availability of these medications to improve
the outcome of children living in poorer countries. One of
the main aims of the study is to promote the regular use
of quantitative clinical measures and the incorporation of
parent- and child-reported outcomes in routine clinical
care. It is now widely agreed that the shift toward a clinical
care based on quantitative measurements leads to a more
rational monitoring of the disease course over time and
the effectiveness of therapeutic interventions. Notably, the
use of a standardized and uniform set of clinical instru-
ments across international pediatric rheumatology centers
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characteristics, outcome and treatment results are com-
parable. The ultimate aim of the EPOCA study is to con-
tribute to improve the quality of care of children with JIA.
Competing interests
The authors declare no conflict of interest.
Author's contribution
AC, NR, GF, AM, and AR have made substantial contributions to study
conception and design; AC, SL, GB, MG, SS, LV, GS, DT, and AZ gave
substantial contribution to acquisition of data; AC, NR, GF, SL, GB, MG, SS, LV,
GS, DT, AZ, AM, and AR have been involved in drafting the manuscript or
revising it critically for important intellectual content, AC, NR, GF, SL, GB, MG,
SS, LV, GS, DT, AZ, AM, and AR gave final approval of the version of the
article to be published.
Author details
1Istituto Giannina Gaslini, Genova, Italy. 2Policlinico S. Orsola-Malpighi,
Bologna, Italy. 3Università degli Studi di Genova, Genova, Italy.
Received: 13 July 2012 Accepted: 10 November 2012
Published: 20 November 2012
References
1. Ravelli A, Martini A: Juvenile idiopathic arthritis. Lancet 2007, 369:767–778.
2. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P,
Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM: Revision
of the proposed classification criteria for juvenile idiopathic arthritis:
Durban, 1997. J Rheumatol 1998, 25:1991–1994.
3. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X,
Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, et al: International League
of Associations for Rheumatology classification of juvenile idiopathic
arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390–392.
4. Martini A: Are the number of joints involved or the presence of psoriasis
still useful tools to identify homogeneous disease entities in juvenile
idiopathic arthritis? J Rheumatol 2003, 30:1900–1903.
5. Andersson Gare B: Juvenile arthritis–who gets it, where and when? A
review of current data on incidence and prevalence. Clin Exp Rheumatol
1999, 17:367–374.
6. Aggarwal A, Misra R: Juvenile chronic arthritis in India: is it different from
that seen in Western countries? Rheumatol Int 1994, 14:53–56.
7. Arguedas O, Fasth A, Andersson-Gare B, Porras O: Juvenile chronic arthritis
in urban San Jose, Costa Rica: a 2 year prospective study. J Rheumatol
1998, 25:1844–1850.
8. Manners PJ, Bower C: Worldwide prevalence of juvenile arthritis why
does it vary so much? J Rheumatol 2002, 29:1520–1530.
9. Ilowite NT: Current treatment of juvenile rheumatoid arthritis. Pediatrics
2002, 109:109–115.
10. Wallace CA: Current management of juvenile idiopathic arthritis. Best
Pract Res Clin Rheumatol 2006, 20:279–300.
11. Lovell DJ: Update on treatment of arthritis in children: new treatments,
new goals. Bull NYU Hosp Jt Dis 2006, 64:72–76.
12. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM,
Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, et al: 2011 American College of
Rheumatology recommendations for the treatment of juvenile
idiopathic arthritis: initiation and safety monitoring of therapeutic
agents for the treatment of arthritis and systemic features. Arthritis Care
Res (Hoboken) 2011, 63:465–482.
13. Davies K, Cleary G, Foster H, Hutchinson E, Baildam E: BSPAR Standards of
Care for children and young people with juvenile idiopathic arthritis.
Rheumatology (Oxford) 2010, 49:1406–1408.
14. Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, Kimura
Y: Disease-modifying Antirheumatic Drug Use in the Treatment of
Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA
Registry. J Rheumatol 2012, 39:1867–1874.
15. Oen K: Long-term outcomes and predictors of outcomes for patients
with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002,
16:347–360.16. Ravelli A: Toward an understanding of the long-term outcome of
juvenile idiopathic arthritis. Clin Exp Rheumatol 2004, 22:271–275.
17. Adib N, Silman A, Thomson W: Outcome following onset of juvenile
idiopathic inflammatory arthritis: I. frequency of different outcomes.
Rheumatology (Oxford) 2005, 44:995–1001.
18. Solari N, Viola S, Pistorio A, Magni-Manzoni S, Vitale R, Ruperto N, Ullmann
N, Filocamo G, Martini A, Ravelli A: Assessing current outcomes of juvenile
idiopathic arthritis: a cross-sectional study in a tertiary center sample.
Arthritis Rheum 2008, 59:1571–1579.
19. Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S, Pistorio A,
Viola S, Ruperto N, Buoncompagni A, Loy A, Martini A, et al: Development
and validation of a new short and simple measure of physical function
for juvenile idiopathic arthritis. Arthritis Rheum 2007, 57:913–920.
20. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G,
Malattia C, Viola S, Martini A, Ravelli A: Development and validation of a
composite disease activity score for juvenile idiopathic arthritis. Arthritis
Rheum 2009, 61:658–666.
21. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia
C, Pederzoli S, Davi S, Martini A, Ravelli A: Remission, minimal disease
activity and acceptable symptom state in juvenile idiopathic arthritis.
Arthritis Rheum 2012, 64(7):2366–2374.
22. Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A: Toward a treat-
to-target approach in the management of juvenile idiopathic arthritis.
Clin Exp Rheumatol 2012, 30(suppl.73):S157–S162.
23. Garcia-Munitis P, Bandeira M, Pistorio A, Magni-Manzoni S, Ruperto N,
Schivo A, Martini A, Ravelli A: Level of agreement between children,
parents, and physicians in rating pain intensity in juvenile idiopathic
arthritis. Arthritis Rheum 2006, 55:177–183.
24. Consolaro A, Vitale R, Pistorio A, Lattanzi B, Ruperto N, Malattia C,
Filocamo G, Viola S, Martini A, Ravelli A: Physicians' and parents' ratings
of inactive disease are frequently discordant in juvenile idiopathic
arthritis. J Rheumatol 2007, 34:1773–1776.
25. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D: Patient-physician
discordance in assessments of global disease severity in rheumatoid arthritis.
Arthritis Care Res (Hoboken) 2010, 62:857–864.
26. Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, Tortorelli
A, Landgraf JM, Singh G, Martini A: Cross-cultural adaptation and
psychometric evaluation of the Childhood Health Assessment
Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32
countries. Review of the general methodology. Clin Exp Rheumatol 2001,
19:S1–S9.
27. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni-
Manzoni S, Ruperto N, Pistorio A, Pederzoli S, Civino A, et al: A new approach
to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis
Multidimensional Assessment Report. J Rheumatol 2011, 38:938–953.
28. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N,
Rossi F, Bartoli M, Martini A, Ravelli A: Development and validation of a
clinical index for assessment of long-term damage in juvenile idiopathic
arthritis. Arthritis Rheum 2005, 52:2092–2102.
29. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B,
Consolaro A, Magni-Manzoni S, Galasso R, Varnier GC, et al: Evaluation of
21-numbered circle and 10-centimeter horizontal line visual analog
scales for physician and parent subjective ratings in juvenile idiopathic
arthritis. J Rheumatol 2010, 37:1534–1541.
30. Filocamo G, Schiappapietra B, Bertamino M, Pistorio A, Ruperto N, Magni-
Manzoni S, Lanni S, Saad-Magalhaes C, Galasso R, Lattanzi B, et al: A new
short and simple health-related quality of life measurement for
paediatric rheumatic diseases: initial validation in juvenile idiopathic
arthritis. Rheumatology (Oxford) 2010, 49:1272–1280.
31. Filocamo G, Consolaro A, Schiappapietra B, Ruperto N, Pistorio A, Solari N,
Pederzoli S, Verazza S, Martini A, Ravelli A: Parent and child acceptable
symptom state in juvenile idiopathic arthritis. J Rheumatol 2012, 39:856–863.
doi:10.1186/1546-0096-10-39
Cite this article as: Consolaro et al.: Seeking insights into the
EPidemiology, treatment and Outcome of Childhood Arthritis through a
multinational collaborative effort: Introduction of the EPOCA study.
Pediatric Rheumatology 2012 10:39.
